LIDDS

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid. With NanoZolid, LIDDS can formulate drugs for local administration that have a controlled and maintained release for up to six months. The technology is versatile and can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid technology to partners and has developed its own pipeline focused on oncology, where the technology enables drug delivery locally and in high dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early- and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth market... LIDDS is based on the proprietary drug delivery technology NanoZolid, a versatile technology that can be used to formulate most drugs and solve problems within many indication areas, offering..

Also known as: LIDDS AB, LIDDS AB (publ)

Registration numbers: 556580-2856 (W)

Primary location: Göteborg Sweden